Search research articles
Contact Us
Filters
Showing results (211-220 of 224) with videos related to
Page
of 23
Sort By:
Radiation Research
|
September 4, 2008
NASA Radiation Biomarker Workshop, September 27-28, 2007
Tore Straume, Sally A Amundson, William F Blakely, et al.
British Journal of Cancer
|
July 29, 2015
Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters
M A Versluis, R A de Jong, A Plat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R E Miller, A Leary, C L Scott, et al.
Genes, Chromosomes & Cancer
|
February 1, 1997
Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations
G Chenevix-Trench, J Kerr, T Hurst, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
S Banerjee, A M Oza, M J Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 9, 2021
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
J E Martin, S Khalife-Hachem, T Grinda, et al.
Breast Cancer Research : BCR
|
March 2, 2006
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource
Graham J Mann, Heather Thorne, Rosemary L Balleine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
I Ray-Coquard, A Leary, S Pignata, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
March 26, 2019
Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa
V Lavoue, C Huchon, C Akladios, et al.
Journal of Gynecology Obstetrics and Human Reproduction
|
April 3, 2019
Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up)
V Lavoue, C Huchon, C Akladios, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 224) with videos related to
Sort By:
Page
of 23
Radiation Research
|
September 4, 2008
NASA Radiation Biomarker Workshop, September 27-28, 2007
Tore Straume, Sally A Amundson, William F Blakely, et al.
British Journal of Cancer
|
July 29, 2015
Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters
M A Versluis, R A de Jong, A Plat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R E Miller, A Leary, C L Scott, et al.
Genes, Chromosomes & Cancer
|
February 1, 1997
Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations
G Chenevix-Trench, J Kerr, T Hurst, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2018
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
S Banerjee, A M Oza, M J Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 9, 2021
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
J E Martin, S Khalife-Hachem, T Grinda, et al.
Breast Cancer Research : BCR
|
March 2, 2006
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource
Graham J Mann, Heather Thorne, Rosemary L Balleine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
I Ray-Coquard, A Leary, S Pignata, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
March 26, 2019
Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa
V Lavoue, C Huchon, C Akladios, et al.
Journal of Gynecology Obstetrics and Human Reproduction
|
April 3, 2019
Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up)
V Lavoue, C Huchon, C Akladios, et al.
Page
of 23